Andrew Cittadine - Jun 13, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Operating Officer
Signature: /s/ Kim R Tsuchimoto, Attorney-in-fact
Stock symbol: MNPR
Transactions as of: Jun 13, 2024
Transactions value $: $32,894
Form type: 4
Date filed: 6/17/2024, 06:08 PM
Previous filing: Jun 5, 2024
Next filing: Jun 21, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Purchase	$10.9K	+12K	+10.2%	$0.91	130K	Jun 13, 2024	Direct
transaction	MNPR	Common Stock	Purchase	$11.2K	+12K	+9.26%	$0.93	142K	Jun 14, 2024	Direct	F1
transaction	MNPR	Common Stock	Purchase	$10.8K	+12K	+8.47%	$0.90	154K	Jun 17, 2024	Direct

Showing 1 to 3 of 3 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9100 to $0.93994, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9100 to $0.93994, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.